Update on Takayasu's arteritis

Alıbaz-Öner, Fatma; Direşkeneli, Haner

doi:10.1016/j.lpm.2015.01.015

Cited by 43 publications

(23 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The variability in physician practices seen in this study regarding the use of imaging in TAK reflects the uncertainty regarding the utility of the imaging modalities from the available literature 20,22. Conventional arteriography was infrequently performed by the surveyed physicians; it is an invasive test that only captures late findings of TAK and cannot visualize inflammation of the vessel wall.…”

Section: Discussionmentioning

confidence: 97%

“…Conventional arteriography was infrequently performed by the surveyed physicians; it is an invasive test that only captures late findings of TAK and cannot visualize inflammation of the vessel wall. CTA was also avoided when possible, given that it is less sensitive than MRA and PET at detecting early vessel wall changes22,23 and exposes patients to radiation and the risk of renal toxicity. In the survey, PET was infrequently used first line.…”

Section: Discussionmentioning

confidence: 99%

“…PET lacks detailed anatomic information, making it less specific for TAK; it is often used in combination with computed tomography with some concern regarding radiation exposure 23,24. Arterial Doppler was also infrequently used; this modality is limited to superficial vessels and is highly user dependent 22,23. Limitations of MRA considered by the surveyed physicians included contraindications to MRA (stent placement and other metal implantations, severe renal disease, etc.)…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey

Barra

Liang

Benseler

et al. 2017

OARRR

View full text Add to dashboard Cite

ObjectiveTakayasu arteritis (TAK) is a large vessel vasculitis that predominately affects young women and can cause severe ischemic complications. Given the rarity of TAK, the management of this condition is challenging. We aim to describe current rheumatologist practices for the management of TAK and identify discrepancies and gaps in knowledge.MethodsAn online survey (developed by the Canadian Vasculitis Network and approved by the Canadian Rheumatology Association) containing 48 questions with regard to the diagnosis, monitoring and treatment of TAK was distributed to 495 Canadian adult and pediatric rheu-matologists by email.ResultsSixty-six rheumatologists completed the survey (13% response rate): the majority (73%) were from academic centers and ≤25% reported managing more than ten patients in their career. For establishing the diagnosis of TAK, they relied on a combination of signs and symptoms of ischemia, elevations of inflammatory markers and vascular imaging (typically computed tomography and magnetic resonance angiography). The frequency of monitoring for disease activity and the methods employed (clinical, laboratory or imaging) were variable. All physicians used corticosteroids for the treatment of TAK, but 42% would treat for at least 6–12 months, 26% for 12–24 months and 23% would never stop corticosteroids. Fifty-three percent would always use an immunosuppressant (most commonly methotrexate or azathioprine) in addition to corticosteroids and the remainder would only start an immunosuppressant in patients with refractory or relapsing disease.ConclusionPhysician practices for the management of TAK are variable, suggesting that there are knowledge gaps, which may impact outcomes in patients with TAK.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey

Barra

Liang

Benseler

et al. 2017

OARRR

View full text Add to dashboard Cite

show abstract

“…Imaging studies of the arterial tree are essential for ascertaining the diagnosis of TA and for determining the extent and severity of vascular involvement [6].…”

Section: Diagnosismentioning

confidence: 99%

Large-Vessel Vasculitides: Takayasu Arteritis and Giant Cell Arteritis

Cavalli

Luca

Dagna

2019

Visceral Vessels and Aortic Repair

View full text Add to dashboard Cite

“…Основан-ное на результатах ретроспективных наблюдательных ис-следований стандартное лечение глюкокортикоидами (ГК) и цитостатиками, прежде всего метотрексатом (МТ) [9], может быть недостаточным для достижения полной устойчивой ремиссии АТ. Так, D. Freitas и соавт.…”

unclassified

Innovative Treatments for Takayasu’s Arteritis: A Focus on Interleukin-6 Inhibitors. The Authors’ Experience With Tocilizumab and a Review of Literature

Бекетова¹,

Насонов²

2017

rsp

View full text Add to dashboard Cite

Update on Takayasu's arteritis

Cited by 43 publications

References 90 publications

Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey

Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey

Large-Vessel Vasculitides: Takayasu Arteritis and Giant Cell Arteritis

Innovative Treatments for Takayasu’s Arteritis: A Focus on Interleukin-6 Inhibitors. The Authors’ Experience With Tocilizumab and a Review of Literature

Contact Info

Product

Resources

About